Publication: Overexpression of proCOL11A1
as a stromal marker of breast cancer
Authors
Fuentes Martínez, Nelson ; García Pravia, Carmen ; García Ocaña, Marcos ; Menéndez Rodríguez, Primitiva ; Del Amo, Jokin ; Suárez Fernandez, Laura ; Galván, José A. ; De los Toyos, Juan R. ; Barneo, Luis
item.page.secondaryauthor
item.page.director
Publisher
F. Hernández y Juan F. Madrid. Universidad de Murcia: Departamento de Biología Celular e Histología
publication.page.editor
publication.page.department
DOI
https://doi.org/10.14670/HH-30.87
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Background: Our previous studies
demonstrated the expression of procollagen11A1 in
fibroblasts of pancreatic cancer desmoplasia and the lack
of expression in fibroblasts of pancreatitis by means of
the polyclonal antibody (anti-proCOL11A1 pAb) we
generated. In a similar way, we decided to compare the
expression of procollagen11A1 in fibroblasts of
infiltrating ductal carcinoma of the breast and fibroblasts
of benign sclerosing lesions of the breast, in order to
validate the anti-proCOL11A1 pAb in this setting and to
study how proCOL11A1 expression relates to other
prognostic and predictive factors, as well as to survival.
Methods: 45 core biopsies of sclerosing adenosis and 50
core biopsies of infiltrating ductal carcinoma of the
breast were stained with anti-proCOL11A1 pAb, a
polyclonal antibody highly specific to the less
homologous fraction of proCOL11A1 (in comparison
with proCOL5A1 and proCOL11A2). In addition, the
expression of the proCOL11A1 gene was measured by
RT-qPCR. On the other hand, the expression of
proCOL11A1 was compared to the expression of
estrogenic receptors, progestagen receptors, the state of
the epidermal growth factor receptor 2 (HER2), the
histologic grade and the stage of the disease. We also
compared the immunohistochemical expression of
proCol11A1 to the disease-free interval, and to overall
survival. Results: The immunohistochemical analysis
showed that proCOL11A1 was expressed in 100% of
infiltrating ductal carcinomas, but only focally expressed
in 2.2% (1 case) of sclerosing adenosis, in agreement
with RT-qPCR results. ProCOL11A1 expression did not
prove to have a prognostic value in relation to the
disease-free interval or to overall survival in infiltrating
ductal carcinoma. Conclusion: The anti-proCOL11A1
pAb is a stromal marker for breast cancer and the
expression of proCOL11A1 does not seem to have a
prognostic value in infiltrating ductal carcinoma of the
breast.
publication.page.subject
Citation
Histology and Histopathology, Vol. 30, n.º 1 (2015)
item.page.embargo
Ir a Estadísticas
Este ítem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by-nc-nd/4.0/